Follow-On Falloff: R&D Slowdown May Reflect Fewer “Me Toos” – Temple
Executive Summary
The decline in new molecular entity approvals may reflect decreasing interest by industry in the development of "me too" agents, FDA Office of Medical Policy Director Robert Temple said